The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

How does biology affect treatment strategy in Waldenström's macroglobulinemia?

Sep 11, 2020

During the 46th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the Lymphoma Hub spoke to Véronique Leblond, L’Hôpital Universitaire Pitié Salpêtrière, Paris, FR, about the impact of the mutational profile of patients with Waldenström's macroglobulinemia (WM) on treatment strategy.

How does biology affect treatment strategy in Waldenström's macroglobulinemia?

In this video, Véronique Leblond highlights that the most important mutations in WM are in MYD88, CXCR4, and TP53, which are found in 90%, 30%, and 10% of patients, respectively. MYD88 mutations can be used as a diagnostic and prognostic tool in WM. We asked, How does biology affect treatment strategy in Waldenström's macroglobulinemia?, to delve further into this subject.

Your opinion matters

At this year’s virtual ESH Meeting, the Lymphoma Hub Satellite Symposium will evaluate treatment options in patients with R/R DLBCL. What do you think is the most promising emerging therapy in this setting?
4 vote s - 17 hours left ...

Newsletter

Subscribe to get the best content related to lymphoma & CLL delivered to your inbox every month